New immunotherapy aims to wipe out hidden HPV after cancer treatment
NCT ID NCT05363709
First seen Jan 17, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study was designed for people with HPV-positive oropharyngeal cancer who still have signs of the virus in their blood after finishing standard treatment. The goal was to see if an immunotherapy drug called BALSTILIMAB could clear the virus and improve long-term survival. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.